Trial Profile

A phase II/III study of DYN101 in Centronuclear Myopathies

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 30 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DYN-101 (Primary)
Indications Congenital structural myopathies
Focus Registrational; Therapeutic Use
Sponsors Dynacure; Flamingo Therapeutics

Most Recent Events

02 Mar 2023 According to a Flamingo Therapeutics media release, Dynacure has merger with Flamingo Therapeutics and subsequently the combined named as Flamingo Therapeutics.
10 Nov 2021 According to a Dynacure media release, this study is expected to begin in 2023.
30 Jul 2020 According to a Dynacure media release, it expect to open a pediatric study in the end of 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com